Skip to main content

Day: February 14, 2024

Verizon to deliver 5G to Fort Bliss Army Post

EL PASO, Texas, Feb. 14, 2024 (GLOBE NEWSWIRE) — Verizon today participated in a groundbreaking ceremony at Fort Bliss, in El Paso, Texas. The event marked the beginning of construction for a new cell tower that will be constructed by Boldyn Networks, with network service provided by Verizon. The tower will service military personnel in Texas and New Mexico. The total investment in the project is $1 million. Military families, personnel, and visitors at Fort Bliss will experience improved wireless coverage and enhanced network services as a result of the new infrastructure. “Verizon supports our military partners through a number of innovative products and services, from 5G deployments, including Private 5G, to improved enterprise infrastructure,” said Martin Mallady, associate director for Verizon’s DoD business. “At the core,...

Continue reading

Glorious Creation Announces Proposed Acquisition of Uranium Assets in the Eastern Athabasca Basin of Saskatchewan, from Stallion Uranium Corp.

Exhibit #1Ford Lake, Cigar Lake East, and Roughrider South shown above with all other Uranium activity in the general region.VANCOUVER, British Columbia, Feb. 14, 2024 (GLOBE NEWSWIRE) — Glorious Creation Limited (“Glorious” or the “Company”) (CSE: GCIT.X) is pleased to announce that the Company has entered into a definitive purchase and sale agreement (the “Definitive Agreement”) dated February 12, 2024 with Stallion Uranium Corp. (“Stallion”), a British Columbia mineral exploration company with its common shares listed for trading on the TSX Venture Exchange (the “TSXV”). Pursuant to the Definitive Agreement, the Company will acquire three separate mineral properties comprised of an aggregate of seven mineral claims, covering a total of 10,874 hectares (approximately 100 square kilometers), located in Eastern Athabasca...

Continue reading

RevoluGROUP Canada Inc. Announces Change to Board of Directors

Vancouver, BC, Feb. 14, 2024 (GLOBE NEWSWIRE) — RevoluGROUP Canada Inc. (TSX-V: REVO), (Frankfurt: IJA2) (the “Company”) announces that Daniel Hernandez, Director of RevoluGROUP has decided to step down effective immediately, and is pleased to announce the appointment of Francisco José Moreno Balboa to the board of directors (the “Board”) of the Company, both effective February 12, 2024. Daniel Hernandez began as a highly valued corporate advisor in September 2017. Since November 2020, Mr. Hernandez has been an instrumental board member, bringing his expertise and guidance to the Company over the past three years. The board and Management extend their deepest gratitude to Daniel for his significant contributions in his previous executive management role. Due to the tremendous success of Daniel Hernandez’s eSignus, a Company...

Continue reading

Brunswick Corporation Named to the Forbes America’s Best Large Employers List for the Sixth Consecutive Year

METTAWA, Ill, Feb. 14, 2024 (GLOBE NEWSWIRE) — For the sixth consecutive year, Brunswick Corporation (NYSE: BC), the world’s largest recreational marine technology company, has been named one of America’s Best Large Employers for 2024 by Forbes Magazine. Of the thousands of companies that were surveyed for this recognition, only 600 made the list. “We are honored to once again see Brunswick recognized as one of America’s top employers. This award reflects direct feedback from our global workforce of more than 17,000 employees, which is a testament to our authentic ‘One Brunswick’ culture,” said Jill Wrobel, Executive Vice President and Chief Human Resources Officer, Brunswick Corporation. “Across our global footprint, we value diversity and are passionate about inspiring innovation. I thank our employees for living...

Continue reading

Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference

HANOVER, MD, Feb. 14, 2024 (GLOBE NEWSWIRE) — Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for more patients suffering from cancer, announces that CEO George Ng will present a corporate update at The Winter Wrap-Up MicroCap Rodeo 2024 Virtual Conference being held February 20 – 23, 2024. Presentation Date: Tuesday, February 20, 2024 Time: 1:30pm ET Webcast Link: https://www.webcaster4.com/Webcast/Page/3023/49969 Mr. Ng will be available for one-on-one meetings throughout the conference. Investors can attend the conference and request a meeting with Mr. Ng by registering here: https://www.microcaprodeo.com/ About Processa Pharmaceuticals, Inc. Processa is a...

Continue reading

Fresh Tracks Therapeutics Urges Stockholders to Vote at the Upcoming Special Meeting on February 15th

Stockholders of record on January 11, 2024 who have not yet voted are encouraged to do so by 11:59 p.m. Eastern Time on February 14, 2024 BOULDER, Colo., Feb. 14, 2024 (GLOBE NEWSWIRE) — Fresh Tracks Therapeutics, Inc. (OTC: FRTX) (“Fresh Tracks” or the “Company”) would like to remind its stockholders to vote their proxy ahead of the Company’s upcoming special meeting of stockholders on February 15, 2024 (the “Special Meeting”) at 12:00 p.m. Eastern Time to seek stockholder approval of the liquidation and dissolution of the Company (the “Dissolution”) and the plan of liquidation and dissolution (the “Plan of Dissolution”). All stockholders of record of the Company’s outstanding shares of common stock at the close of business on January 11, 2024 may participate and vote at the Special Meeting. The Special Meeting on February 15,...

Continue reading

ImagineX Bolsters Software Engineering Capabilities with Build

Atlanta, GA, Feb. 14, 2024 (GLOBE NEWSWIRE) — ImagineX, an Atlanta, Georgia-based digital services firm specializing in software engineering and cybersecurity services, is pleased to announce its partnership with Build, a prominent software engineering firm. Founded in 2018, Build adds a 50-person software engineering team in Costa Rica to ImagineX’s existing base of US-based technology team members. By uniting with Build, ImagineX accelerates its mission to cater to the diverse needs of large enterprise clients. The existing expertise within ImagineX combined with Build’s extensive experience in enterprise-caliber custom software solutions creates a dynamic partnership, positioning the combined business to serve the evolving demands of enterprises in a rapidly changing digital landscape. Shaun Bank, CEO of ImagineX, expressed...

Continue reading

Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight

Event, moderated by Hartaj Singh and Eka Gigauri of Oppenheimer & Co., will be held on Thursday, February 22, 2024 at 11:00 am EST BETHESDA, Md., Feb. 14, 2024 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc., (Nasdaq: GANX), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced it is holding a 2024 Research & Development update on recent in vivo data for GT-02287 along with valuable insights from Key Opinion Leaders. Event Details “Beyond Symptomatic Treatment of Parkinson’s Disease: Gain Therapeutics R&D Update with KOL & Analyst Insights 2024” Date: February 22nd, 2024 Time: 11:00 am – 12:00 pm EST Register for the Event HERE. Send any questions you’d like answered in our Q&A to ir@gaintherapeutics.com. Discussion...

Continue reading

Limitless X Announces Filing of Registration Statement on Form S-1

LOS ANGELES, Feb. 14, 2024 (GLOBE NEWSWIRE) — Limitless X Inc (OTCQB: VYBE) stands as an omnipresent consumer packaged goods enterprise, focusing on the creation and provision of products under the ‘Look Good, Feel Great’ theme within the nutrition and beauty sectors, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (the “SEC”) relating to public offering of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Additionally, the company has strong relationships with multiple underwriters...

Continue reading

AMG Schedule for Fourth Quarter and Full Year 2023 Earnings Release

Amsterdam, 14 February 2024 — AMG Critical Materials N.V. (“AMG”, EURONEXT AMSTERDAM: “AMG”) will release its fourth quarter and full year 2023 financial results on Wednesday, February 21, 2024, at approximately 18:00 CET. AMG will host a conference call to discuss its financial results for the fourth quarter of 2023 at 19:00 CET (18:00 GMT / 1:00PM EST) on Wednesday, February 21, 2024. Please connect approximately 10 minutes prior to the beginning of the call to ensure participation. The call-in information is as follows: Toll-free number:                1-800-267-6316 Alternate (toll) number:        1-203-518-9783 United Kingdom:                44 0800 048 7798 Netherlands:                        31 0800 022 9530 When prompted for the conference ID, tell the operator AMGQ423 and you will be directed onto...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.